Kindstar Globalgene Technology, Inc (9960) Fair Value & Analysis
Healthcare · HK · Market cap HK$1.0B
Fair value as of: Aug 6, 2026
From 9 valuation models · updated 4 days ago
Share price −1.5% over the past month.
Below-average quality, and screening another 39% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.7800). The favourable scenario is already priced in.
- Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (HK$0.4000 to HK$0.7800) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 6, 2026.
How to read this chart
60‑month range HK$0.8570 – HK$8.17 · fair‑value band HK$0.4000 – HK$0.7800 · the HK$0.9650 price screens above the HK$0.5900 fair value. Dashed = 300-day average. As of Aug 6, 2026.
Analysis
Kindstar Globalgene Technology, Inc (9960) currently trades at HK$0.9650, while our model-based Fair Value estimate is HK$0.5900, implying the stock looks roughly 38.9% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Kindstar Globalgene Technology, Inc generated revenue of HK$934M at a net margin of -6.3%. Revenue grew 4.9% year over year. It earns a return on equity of -2.0%. Net debt stands at HK$47.5M. Fundamentals as of Aug 6, 2026
Our scenario range runs from HK$0.4000 (bear case) to HK$0.7800 (bull case); at HK$0.9650, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -39%, 9960 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 9 models by family
Widest divergence: Asset-Based (HK$1.77) versus Dividend Discount (HK$0.1900). Highest evidence: Growth DCF (80).
Notify me when 9960 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 6, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Kindstar Globalgene Technology, Inc., an investment holding company, provides clinical testing services in the People's Republic of China and Mainland China. It operates through nine segments: Hematology Testing.
Full company description
Kindstar Globalgene Technology, Inc., an investment holding company, provides clinical testing services in the People's Republic of China and Mainland China. It operates through nine segments: Hematology Testing. Genetic Diseases and Rare Diseases, Infectious Diseases, Oncology, Neurology, Maternity-Related Diseases, Routine Testing, CROs and R&D Project, and Others. The company offers esoteric testing services for hematology, oncology, neuroscience and infectious diseases. It also engages in product development and technical services; reagent development and sales; car-t treatment; and E-commerce services. The company's research and development projects, including molecular biology detection, flow cytometry detection, cytogenetic detection, and pathological detection technologies. Kindstar Globalgene Technology, Inc. was founded in 2003 and is headquartered in Wuhan, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kindstar Globalgene Technology, Inc reported revenue of HK$934M in FY2025 versus HK$931M in FY2021, a compound +0.1%/yr. Reported net income was −HK$58.7M in FY2025.
9960 screens 39% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Kindstar Globalgene Technology, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kindstar Globalgene Technology, Inc (9960) overvalued or undervalued?
What is the fair value of 9960?
What is the quality score of 9960?
What is the revenue of Kindstar Globalgene Technology, Inc (9960)?
What is the net profit margin of 9960?
Does Kindstar Globalgene Technology, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Kindstar Globalgene Technology, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.